Janeen Noel Doyle
CIK: 0002069239
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)1 (33.3%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (66.7%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
JANX
Janux Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
About Doyle Janeen Noel
Doyle Janeen Noel (SEC CIK 0002069239) files insider reports with the SEC as Chief Corp. & Bus. Dev. Ofcr of Janux Therapeutics, Inc. (JANX).
Signal8 holds 4 ownership filings by Doyle Janeen Noel (1 Form 3, 3 Form 4), filed between May 23, 2025 and Jun 4, 2026. Those filings report 3 transactions, from Jun 2, 2025 to Jun 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Doyle Janeen Noel's filings is in SAN DIEGO, CA.
Recent filings by Doyle Janeen Noel
Other insiders filing for Janux Therapeutics, Inc. (JANX)
- Campbell David Alan, President and CEO
- RA CAPITAL MANAGEMENT, L.P., Director
- Simson Jake, Director
- Kung Winston, Director
- Hernday Natasha, Director
- DOBMEIER ERIC, Director